Wikström Pernilla, Lissbrant Ingela Franck, Stattin Pär, Egevad Lars, Bergh Anders
Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Prostate. 2002 Jun 1;51(4):268-75. doi: 10.1002/pros.10083.
Endoglin, a receptor for some of the members of the transforming growth factor-beta (TGF-beta) family, is expressed on proliferating endothelial cells and has been suggested as a marker of ongoing angiogenesis. In this study, endoglin was evaluated as a prognostic factor for prostate cancer progression.
Immunohistochemical staining of endoglin was examined in 72 cases of prostate cancer and compared with immunohistochemical staining of the pan-endothelial marker von Willebrand factor (vWf), clinicopathological factors, and cancer-specific survival. Micro-vessels were measured in the most vascularized fields. Double staining with antibodies against smooth muscle actin and endoglin or vWf, respectively, was performed in order to evaluate vessel maturation.
Endoglin-stained tumor vessels were generally small and only 19% also stained with actin. Endoglin was a better prognostic marker than vWf. The median survival times were shorter for patients with tumor vascular count (vc) above median than for patients with vc below median (4 vs. 12 years, P = 0.0007, and 5 vs. 10 years, P = 0.018, for endoglin and vWf, respectively). Endoglin vc was associated with Gleason score (P = 0.001), local tumor stage (P = 0.0006), metastasis (P = 0.01), tumor cell immunoreactivity for TGF-beta1 (P = 0.0003), and tumor cell proliferation index (r(s) = 0.319, P = 0.02). Endoglin, in contrast to vWf, vc was prognostic for survival in the subgroup of patients with Gleason score 5, 6, and 7 tumors.
Endoglin marks principally small, probably newly formed tumor vessels in zthe prostate, and is a promising prognostic marker for prostate cancer patients.
内皮糖蛋白是转化生长因子-β（TGF-β）家族某些成员的受体，在增殖的内皮细胞上表达，被认为是正在进行的血管生成的标志物。在本研究中，评估内皮糖蛋白作为前列腺癌进展的预后因素。
对72例前列腺癌病例进行内皮糖蛋白免疫组织化学染色，并与全内皮标志物血管性血友病因子（vWf）的免疫组织化学染色、临床病理因素及癌症特异性生存情况进行比较。在血管化程度最高的区域测量微血管。分别用抗平滑肌肌动蛋白和内皮糖蛋白或vWf的抗体进行双重染色，以评估血管成熟度。
内皮糖蛋白染色的肿瘤血管通常较小，只有19%也被肌动蛋白染色。内皮糖蛋白是比vWf更好的预后标志物。肿瘤血管计数（vc）高于中位数的患者中位生存时间短于vc低于中位数的患者（内皮糖蛋白和vWf分别为4年对12年，P = 0.0007；5年对10年，P = 0.018）。内皮糖蛋白vc与Gleason评分（P = 0.001）、局部肿瘤分期（P = 0.0006）、转移（P = 0.01）、肿瘤细胞对TGF-β1的免疫反应性（P = 0.0003）及肿瘤细胞增殖指数（r(s)= 0.319，P = 0.02）相关。与vWf不同，内皮糖蛋白vc对Gleason评分5、6和7级肿瘤患者亚组的生存具有预后意义。
内皮糖蛋白主要标记前列腺中可能新形成的小肿瘤血管，是前列腺癌患者有前景的预后标志物。
